Relay Therapeutics (RLAY) awards 475K stock options to executive

Q: How many Relay Therapeutics (RLAY) shares are covered by the new stock option grant?

The new stock option grant covers 475,000 shares of Relay Therapeutics common stock, with the same amount shown as beneficially owned following the transaction.

Q: How do the stock options for the Relay Therapeutics (RLAY) executive vest?

The shares underlying the stock option vest in sixteen equal quarterly installments after January 13, 2026 , subject to Peter Rahmer’s continued service with Relay Therapeutics through each vesting date.

Q: Is the stock option grant to the Relay Therapeutics (RLAY) executive a direct or indirect holding?

The Form 4 indicates that the 475,000 stock options are held directly (D) by Peter Rahmer.

Q: What is Peter Rahmer’s role at Relay Therapeutics (RLAY) in this Form 4?

The remarks identify Peter Rahmer as the company’s Chief Corporate Development Officer at Relay Therapeutics.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Relay Therapeutics, Inc. reported an insider equity award for Chief Corporate Development Officer Peter Rahmer. On January 13, 2026, he received a stock option covering 475,000 shares of common stock at an exercise price of $7.94 per share.

According to the filing, the shares underlying this option vest in sixteen equal quarterly installments after January 13, 2026, contingent on his continued service with the company through each vesting date. Following this grant, Rahmer beneficially owned 475,000 derivative securities directly in the form of this stock option.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Rahmer Peter

Role See remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	475,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 475,000 shares (Direct)

Footnotes (1)

[object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/15/2026 - 04:13 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rahmer Peter

(Last)

(First)

(Middle)

C/O RELAY THERAPEUTICS, INC.

60 HAMPSHIRE STREET

(Street)

CAMBRIDGE

02139

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Relay Therapeutics, Inc. [ RLAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$7.94	01/13/2026		A		475,000		⁽¹⁾	01/12/2036	Common Stock	475,000	$0.00	475,000	D

Explanation of Responses:

1. The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments after January 13, 2026, subject to the reporting person's continued service with the Issuer through each vesting date.

Remarks:

Chief Corporate Development Officer

	/s/ Soo-Yeun Lim, as Attorney-in-Fact	01/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Relay Therapeutics (RLAY) report in this Form 4?

The Form 4 reports that Chief Corporate Development Officer Peter Rahmer received a stock option covering 475,000 shares of Relay Therapeutics common stock on January 13, 2026.

What is the exercise price of the stock options granted to Peter Rahmer at Relay Therapeutics (RLAY)?

The stock option granted to Peter Rahmer has an exercise price of $7.94 per share for Relay Therapeutics common stock.

How many Relay Therapeutics (RLAY) shares are covered by the new stock option grant?

The new stock option grant covers 475,000 shares of Relay Therapeutics common stock, with the same amount shown as beneficially owned following the transaction.

How do the stock options for the Relay Therapeutics (RLAY) executive vest?

The shares underlying the stock option vest in sixteen equal quarterly installments after January 13, 2026, subject to Peter Rahmer’s continued service with Relay Therapeutics through each vesting date.

Is the stock option grant to the Relay Therapeutics (RLAY) executive a direct or indirect holding?

The Form 4 indicates that the 475,000 stock options are held directly (D) by Peter Rahmer.

What is Peter Rahmer’s role at Relay Therapeutics (RLAY) in this Form 4?

The remarks identify Peter Rahmer as the company’s Chief Corporate Development Officer at Relay Therapeutics.